The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.
S. Bazarbashi
No relevant relationships to disclose
A. H. Aljubran
No relevant relationships to disclose
H. Soudy
No relevant relationships to disclose
A. Darwish
No relevant relationships to disclose
A. Eltigani
No relevant relationships to disclose
M. Nabil-Ahmed
No relevant relationships to disclose
W. Edesa
No relevant relationships to disclose
M. Almubarak
No relevant relationships to disclose
A. Abu sabaa
No relevant relationships to disclose
M. Shoukri
No relevant relationships to disclose